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Objectives: While outcome data on open surgery for
chronic mesenteric ischemia (CMI) exists from single-cen-
ters, risk-adjusted population-based data does not exist.
The objective of this study was to report postoperative
30-day outcomes after open surgery for CMI and analyze
the associated risk factors.
Methods: Patients who underwent open surgery for
CMI were identified from the American College of Sur-
geons’ 2007-09 National Surgical Quality Improvement
Program - a multicenter (more than 180 hospitals), pro-
spective database. Multivariate logistic regression was
performed.
Results: In 178 patients, median age was 65 years with
27.0% being males and 88.2% Caucasians. Median body
mass index (BMI) was 22.5 kg/m2. Comorbidities in-
cluded diabetes (14.6%), chronic obstructive pulmonary
disease (19.7%), prior cardiac surgery/coronary interven-
tion (27.0%), hypertension (75.8%), and renal insufficiency
with serum creatinine (Cr) 1.5 mg/dl (5.1%). Median
(upper quartile-lower quartile) intraoperative transfusion
was 1 units (0-2), operative time 266 minutes (203-328),
and hospital length of stay 8 days (6-13). Twelve patients
(6.7%) underwent thromboendarterectomy, 155 (87.1%)
underwent bypass, and 11 (6.2%) underwent both. Major
morbidity andmortality rates were 34.8% and 6.7%, respec-
tively. Graft failure was seen in 4.5% patients. On multivar-
iate analysis, BMI was associated with mortality (OR 1.4;
95% CI- 1.1 to 1.8; p0.009) and elevated PTT was
associated with morbidity (OR 6.6; 95%CI- 1.1 to 38.9;
p0.04).
Conclusions: Morbidity and mortality rates after open
surgery for CMI among the United States population are
comparable to those reported from single-centers. Patients
with higher BMI and elevated PTT are at increased risk for
adverse events after open surgery.
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Objectives: Prehepatice portal vein obstruction is an
important cause of non-cirrhotic portal hypertension. The
major complications of prehepatic portal hypertension
(PPH) include bleeding esophagogastric varices, hyper-
splenism, and bowel ischemia. The aim of this article is to
discuss the outcomes of surgical and endovascular treat-
ment for the complications from PPH.
Methods: From January 2000 to May 2009, 41 pa-
tients with PPH were treated with open surgery or cathe-
ter-directed thrombolysis. Twenty-nine were male and 12
were female. The median age was 20 years (2 to 54 years).
Thirty-nine patients presented with hypersplenism; 37 had
history of gastrointestinal bleeding; 4 patients complained
of new onset of abdominal pain. Portosystemic shunt was
performed in 34 patients, including 23 mesocaval, 8 sple-
norenal, 2 paraumblilical-jugular, and 1 portocaval shunt.
Esophagogastric devascularization was performed in 3.
Four patients with acute portal vein thrombosis were
treated with catheter-directed thrombolysis. Mean follow
up was 23.4 months (2 to 60 months).
Results: In the 34 patients undergoing portosystemic
shunt, no one had recurrent bleeding. All the 3 patients
with esophagogastric devascularization sustained recurrent
variceal bleeding at 8, 13, and 24 months postoperatively.
One of them died, and the other 2 were converted to
mesocaval shunt. Of the 4 patients undergoing thrombol-
ysis, 3 survived without complication; 1 died due to small
bowel infarction secondary to recurrent portal and mesen-
teric vein thrombosis 40 days later. The 30-day mortality
was zero in this group.
Conclusions: Portosystemic shunt is a safe and effec-
tive treatment for bleeding esophagogastric varices and
severe hypersplenism secondary to PPH. It is more reliable
than esophagogastric devascularization. Endovascular
catheter-directed thrombolysis is an alternative treatment
for acute portal and/or mesenteric venous thrombosis;
however, clinical investigation in a large group of patients is
needed.
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